QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
QIAGEN reported Q2 2026 net sales of $535 million, flat year-over-year but exceeding the outlook for a 2% CER decline, with adjusted diluted EPS of $0.62 topping the $0.60 outlook. Growth pillars delivered 5% CER growth driven by Sample technologies and QIAcuity, while QuantiFERON sales managed a slight increase despite lower U.S. immigration testing demand.
Key figures
- Eps
- $0.50
- Revenue
- $535 million
- Guidance
- Full-year 2026 net sales growth of about 1-2% CER; adjusted diluted EPS of at least $2.43 CER
- Revenue Yoy
- 0%
- Adjusted eps
- $0.62
- Dividend increase
- 40%
- Operating cash flow h1
- $301 million
- Operating income margin
- 29.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.